Denagard 10

This treatment applies to the following species:

Swine

Company: Elanco (Farm Animal)

(tiamulin hydrogen fumarate)

Type B Medicated Swine Feed

Active Ingredient

Tiamulin hydrogen fumarate: 10 g/lb

GUARANTEED ANALYSIS

Crude Fat, not less than	4%
Crude Fiber, not more than	50%
Crude Protein, not less than	1%

Ingredients: rice hulls, mineral oil, porcine gelatin

For Manufacture of Type C medicated swine feed only.

Do not feed undiluted.

Denagard 10 Indications	Amount of Type B Medicated Feed Per Ton of Feed	Tiamulin hydrogen fumarate in Complete Type C Medicated Feed Per Ton	Withdrawal Period (days)
For treatment of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hyodysenteriae susceptible to Tiamulin	20 lb	200 g	7
For control of porcine proliferative enteropathies (ileitis) associated with Lawsonia intracellularis	3.5 lb	35 g	2
For control of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hyodysenteriae susceptible to Tiamulin	3.5 lb	35 g	2

Warnings

Observe withdrawal time shown in table above.

Keep out of reach of children. Avoid contact with skin. Direct contact with skin or mucous membranes may cause irritation.

Denagard 10 Caution

Do not feed undiluted. Do not use in feeds for animals other than swine. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined. Swine being treated with Denagard (tiamulin) should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin and semduramicin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.

Mixing Directions

Mix this medicated feed (Type B) with non-medicated feed ingredients to make a Type C medicated feed as follows:

Type C Medicated Feed Tiamulin grams/ton Feed	Pounds Medicated Feed (Type B)	Pounds Non-medicated Feed*
35	3.5	1996.5
200	20	1980

*When making an approved Type C medicated feed drug combination, the inclusion rate of this non-medicated feed should be adjusted for the amount of the other drug added to make such combination Type C medicated feed.

Storage

Store at or below 25°C (77°F). Temporary excursions to 40°C (104°F) permitted.

To report adverse effects, access medical information, or obtain additional product information call 1-800-428-4441

For a complete listing of adverse reactions for DENAGARD reported to CVM see:

www.fda.gov/reportanimalae

Denagard, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

Restricted Drug (California): Use only as directed.

Approved by FDA under NADA # 139-472

Marketed by: Elanco US, Inc., Greenfield, IN 46140

Net Weight:
35 lb (15.9 kg)	BG101792X

CPN: 1114102.6

ELANCO US, INC.
Distributed by ELANCO US, INC.
2500 INNOVATION WAY, GREENFIELD, IN, 46140

Customer Service:		317-276-1262
Technical Service:		800-428-4441
Website:		www.elanco.us
Email:		elanco@elanco.com

THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.